Kane Biotech (TSE:KNE) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Kane Biotech Inc. has entered into a global licensing agreement with Omni Bioceutical Innovations for the distribution of its coactiv+™ scalp care product line. The five-year deal allows Omni to market Kane’s innovative scalp detoxifier under their brand, targeting the medical aesthetics market. The partnership is poised to leverage the product’s proven efficacy in addressing common scalp conditions without harsh chemicals.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
